Evotec AG increases its revenue guidance
All other elements of the Company's financial guidance as of 12 May 2015 are confirmed.
Evotec's Group EBITDA before changes in contingent considerations is expected to be positive.
Evotec expects research and development (R&D) expenses to grow to EUR 15 m - EUR 20 m in 2015.
Evotec will continue to invest in its technology platforms and capacities in order to drive its long-term growth strategy. It is therefore planned that up to EUR 10 m will be invested in further capacity increases and the upgrade of Evotec's technological capabilities. Liquidity is expected to be well in excess of EUR 100 m at 31 December 2015. This forecast excludes any potential cash outflow from M&A or similar transactions.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.